Event Date

December 5-7, 2019

Event Location


Send us an email


Register Now!

Save $200 for Earlybird

Latest News

•  Online Registration is Open
March 1st, 2019

•  Call for speakers!
February 1st, 2019

•  Save $200 for Earlybird Registration before April 30th, 2019

Important Dates

•  Abstract Submission Start Day
February 1st, 2019

•  Earlybird Registration Start Day
March 1st, 2019

•  Earlybird Registration Deadline
April 30th, 2019

•  Abstract Submission Deadline
October 15th, 2019

•  Acceptance Notification Deadline
November 5th, 2019



Welcome Message


On behalf of the Organizing Committee, it gives our great pleasure to welcome you to The International Congress of Cancer & Clinical Oncology (CCCO-2019) to be held from December 5-7, 2019 in Singapore.

CCCO-2019 mainly focuses on current hot topics of cancer research and clinical oncology to accelerate the translation of cutting edge discovery from basic science to clinical level, and further promote international scientific cooperation, debate and exchange. It aims to presents a unique platform for prominent surgeons, doctors, academician, scientists and R&D leaders from pharmaceuticals to obtain and exchange information on advances in the basic research, early diagnosis and treatment of cancer, while considering both global and regional aspects.

Through three days meeting, there will be 28 parallel sessions, as well as plenary forum for keynote speeches from distinguished researchers from worldwide, hospital management forum and Industrial Satellite Symposia. We are expecting upwards of 500 participants from all over the world to take part in this event. Poster showcase and table top will run during the same three days. We are confident that over the meeting of the three days there will be something to whet everyone's appetite!

Finally, we are looking forward to welcoming you all to this enriching and stimulating meeting. Hope you will enjoy your stay in the Singapore.

Keynote Presenters

Title: Metabolic and Immune Regulation of Liver Cancer and Its Treatment

Dr. Michael Karin, Distinguished Professor, University of California, San Diego, USA

Dr. Karin received his BSc in Biology from Tel Aviv University in 1975 and his Ph.D. in Molecular Biology from the University of California Los Angeles in 1979. He is currently a Distinguished Professor of Pharmacology and Pathology at the University of California San Diego School of Medicine, where he has been on the faculty since 1986.

Dr. Karin has received numerous awards, including the Endocrine Society Oppenheimer Award for Excellence in 1990, American Cancer Society Research Professorship in 1999, C.E.R.I.E.S. Research Award for Physiology or Biology of the Skin in 2000, Harvey Prize in Human Health in 2011, Brupbacher Prize in Cancer Research in 2013, William B. Coley Award for Distinguished Research in Basic and Tumor Immunology in 2013, and an honorary Doctor of Medicine from the Technical University of Munich. He was a cofounder of Signal Pharmaceutical, which has become a part of Celgene, Inc. Dr. Karin had also served as a member of the National Advisory Council for Environmental Health Sciences. Dr. Karin was elected as a member of the US National Academy of Sciences in 2005, the National Academy of Medicine in 2011 and as an associate member of the European Molecular Biology Association in 2007. He became a fellow of the American Association for Cancer Research Academy in 2017. Dr. Karin’s current activity primarily focuses on understanding the relationship between inflammation, cancer, and metabolic disease as well as the signaling mechanisms used by receptors involved in inflammation and innate immunity. In addition to discovering some of the most important stress- and inflammation-responsive signal transduction pathways and establishing molecular links between obesity, inflammation and cancer, Dr. Karin’s work has revealed new targets for cancer prevention and therapy as well as for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases. Interests:Protein Kinases, Oncogenes, Transcription Factors, Signal Transduction, Gene Expression

Title: Diagnosis of stage I pancreatic cancer saves lives
Dr. Carl Borrebaeck, Professor & Director of CREATE Health Cancer Center, Lund University, Sweden

Professor Carl Borrebaeck received the first chair as professor of Immunotechnology in Scandinavia 1989, when the Department was inaugurated. His main research interests are cancer proteomics, for early detection and prognosis, antibody engineering, for the generation of human therapeutic antibodies and mechanisms and prediction of allergy.

Professor Borrebaeck spent a sabbatical year at the Oklahoma Medical Research Foundation 1996-97 and did his post-doctoral training at the University of California in Davis. Today Professor Borrebaeck is scientific director of CREATE Health a center for Translational Cancer Research at Lund University, where the focus is to work with complex clinical problems using advanced technologies. He is a permanent member of the Royal Swedish Academy of Engineering Sciences. He received the AKZO Nobel Science Award 2009, for his contributions to cancer proteomics and antibody-based therapy, the Research!Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. 2017 he was awarded as Biotech Builder of the year.
Professor Borrebaeck´s research has resulted in several spin-out companies, such as BioInvent International AB, Alligator Bioscience AB, Immunovia AB and SenzaGen AB, focusing on different aspects of diagnosis or therapy of complex diseases. View More at  http://www.immun.lth.se/research/principal-investigators/carl-borrebaeck/biography/

Title: Cancer arising from endometriosis
Dr. Ceana Nezhat, Medical Director, Nezhat Medical Center, USA

Dr. Ceana Nezhat, MD is a world\renowned gynecological surgeon and medical director of Nezhat Medical Center in Atlanta, which specializes in minimally invasive surgical treatment of severe and multi\organ endometriosis, infertility, and urologic and pelvic reconstruction.

He has developed techniques and refined instrumentation for minimally invasive surgery for the benefit of patients globally. The practice is devoted to providing excellent care and service. Dr. Nezhat offers patients decades of gynecological expertise, both surgically, as well as the management and treatment of hormone therapy and reproductive medicine. Dr. Nezhat has treated thousands of patients with a variety of pelvic disorders. Endometriosis is one of his special interests. He advocates its early detection and treatment by educating primary caregivers of young women the signs and symptoms of this debilitating disease. Dr. Nezhat’s innovative research and educational outreach have earned him prestigious honors and recognition from independent medical associations internationally. He is widely sought for teaching and lecturing, and has conducted numerous courses on laparoscopic surgery in the U.S. and abroad. Dr. Nezhat has coauthored several textbooks and over 100 book chapters and articles. He is a member of many distinguished societies, reviewer for several academic journals, and advisor to teaching organizations.

Medical Director, Nezhat Medical Center
Fellowship Director, Atlanta Center for Special Minimally Invasive Surgery & Reproductive Medicine, 1998 – present
Medical Director of Training and Education, Northside Hospital, Atlanta, Georgia, 2012 – present
Director of Minimally Invasive Surgery and Robotics, Northside Hospital, Atlanta, Georgia, 2017 – present
Adjunct Professor of Gynecology & Obstetrics, Emory University School of Medicine
Past President (16-17), Society of Reproductive Surgeons – Still holds the position of Chair,
Domestic Membership Committee, Society of Reproductive Surgeons, 2007 – present Chair, American Society of Reproductive Medicine. Membership Committee, 2013 – present
Past President (13-14), American Association of Gynecology Laparoscopy Board of Directors, Medical Association of Atlanta, 2018 – present
Editorial Board Member, Atlanta Medicine. 2015 – Present
View More at https://endometriosisspecialists.com/about/dr-ceana-nezhat/

Title: Move from Reductionism to Complex Biology and Development of Next Generation Therapies in Oncology

Dr. Harsukh Parmar, Non-Executive Director, Innovator, Entrepreneur & Consultant to The Biotech Industry, UK & USA

Harsukh qualified in Medicine at Aberdeen University and worked at the Imperial medical school for 10 years in academic medicine, immunology and oncology. He later worked for Pfizer, Roche, AstraZeneca & Merck Kga in various senior leadership roles.

and has transitioned more than 120 NME’s from Discovery into Development and Launch of many blockbusters (Rituximab, Voriconazole, Symbicort, Brilinta etc).  He chaired and lead the cross-functional Translational Medicine Leadership Team comprising of both discovery and development functions within AstraZeneca, Medimmune & Roche. He has served on all the major R & D governance committees at all his former companies (ESPC, DRC, DOC etc) and has chaired and been keynote speaker at more than 150 industry and academic conferences and is cited in Marquis Who Who since 1990 for his contributions to science and medicine.

Title: Biomarker-driven Drug Development in Oncology

Dr. Baolin Zhang, Senior Investigator, Lead Product Reviewer, Food and Drug Administration, Center for Drug Evaluation and Research, USA

Dr. Baolin Zhang is a Senior Investigator in the Office of Biotechnology Products of the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA).

Dr. Zhang has 18 years of FDA regulatory experience with extensive and practical knowledge in the development and market approval of biotech products (therapeutic proteins, monoclonal antibodies, ADCs, biosimilars). He also directs multidisciplinary research programs to support regulatory decision making and is Subject Matter Expert for cancer drug development. Dr. Zhang has authored more than 200 peer-reviewed articles, book chapters, and presentations on topics related to cancer drug resistance, cancer biomarker, targeted therapy, and product quality issues. Dr. Zhang received numerous awards including the FDA Scientific Achievement Award and FDA Awards for Excellence in Regulatory Science, Excellence in Analytical Science, Excellence in Mentoring, Excellence in Leadership, and Team Excellence.


Copyright © 2018-2019 ISTCI.ORG All Rights Reserved.